Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system

Journal of Infectious Diseases

Volumn 211, Issue 10, 2015, Pages 1566-1573

  Liu, Jessica ^a   Tseng, Tai Chung ^b,h   Yang, Hwai I ^a,i,j   Lee, Mei Hsuan ^c   Batrla Utermann, Richard ^l   Jen, Chin Lan ^a   Lu, Sheng Nan ^k   Wang, Li Yu ^d   You, San Lin ^a   Chen, Pei Jer ^e,f   Chen, Chien Jen ^a,g   Kao, Jia Horng ^e,f  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b Taipei Tzu Chi Hospital   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Mackay College of Medical   (Taiwan)

^e Division of Gastroenterology   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h TZU CHI UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j CHINA MEDICAL UNIVERSITY   (Taiwan)

^k CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

Epidemiology; Prediction model; Viral hepatitis

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ANTIGEN DETECTION; ARTICLE; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMA CLEARANCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; TAIWAN; UNIVERSITY HOSPITAL; VALIDATION PROCESS; VIRUS LOAD; AGED; BLOOD; CLASSIFICATION; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY; VIROLOGY;

ADULT; AGED; COHORT STUDIES; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TAIWAN;

EID: 84929657961     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu659     Document Type: Article

References (36)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-45.
3. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168-74.
4. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-92.
5. Yang HI, Hung HL, Lee MH, et al. Incidence and determinants of spontaneous seroclearance of HB e antigen and DNA in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10:527-34.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-85.
7. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15:133-43.
8. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51:1531-7.
9. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: A community-based follow-up study. Gastroenterology 2010; 139:474-82.
10. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term followup. Hepatology 2007; 45:1187-92.
11. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37:756-63.
12. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-7.
13. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759-68.
14. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review. Hepatology 2011; 53:2121-9.
15. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011; 55:1121-31.
16. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52:1251-7.
17. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56:1006-11.
18. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 2010; 52:514-22.
19. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139:483-90.
20. Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013; 58:546-54.
21. Chan HL,Wong GL, Tse CH, Chan HY,Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011; 204:408-14.
22. Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141:517-25, 525.e1-2.
23. Lee MH, Yang HI, Liu J, et al. Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013; 58:546-54.
24. Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58:1537-47.
25. Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013; 58:853-60.
26. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
27. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007; 11:797-816, viii.
28. Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55:68-76.
29. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004; 23:1631-60.
30. Heagerty PJ, Lumley T, PepeMS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56:337-44.
31. Ahn SH, Chan HL, Chen PJ, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4:386-95
32. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138:1747-54.
33. Liu J, Yang HI, Lee MH, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014; 63:1648-57.
34. Liu J, Lee M-H, Batrla R, et al. Differences in the role of quantitative hepatitis B surface antigen between HBeAg seropositive and seronegative individuals with chronic hepatitis B. J Hepatol 2012; 56(Suppl 2):S187.
35. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12:568-74.
36. Lee MH, Lu SN, Yuan Y, et al. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014; 9:e94760.